Holen Sie sich die Stockscreener-App
8.10
1.96%
-0.08
Schlusskurs vom Vortag:
$8.18
Offen:
$8.21
24-Stunden-Volumen:
24,802
Relative Volume:
0.83
Marktkapitalisierung:
$55.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-71.37M
KGV:
-0.7515
EPS:
-10.7782
Netto-Cashflow:
$-46.62M
1W Leistung:
+0.00%
1M Leistung:
-0.43%
6M Leistung:
-33.06%
1J Leistung:
-61.85%
1-Tages-Spanne:
$8.08
$8.27
1-Wochen-Bereich:
$7.90
$8.27
52-Wochen-Spanne:
$5.67
$42.79
Instil Bio Inc Stock (TIL) Company Profile
Firmenname
Instil Bio Inc
Sektor
Branche
Telefon
(972) 499-3350
Adresse
3963 MAPLE AVENUE, DALLAS
Compare TIL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
8.17 | 55.48M | 0 | -71.37M | -46.62M | -10.78 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.57 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.44 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.28 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2026-01-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-04-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-01 | Herabstufung | Truist | Buy → Hold |
| 2021-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-04-13 | Eingeleitet | Cowen | Outperform |
| 2021-04-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-04-13 | Eingeleitet | Truist | Buy |
Alle ansehen
Instil Bio Inc Aktie (TIL) Neueste Nachrichten
Instil Bio Inc. (TIL) Q1 2026 Earnings: Wider-Than-Expected Loss as Biotech Continues Pre-Commercial PhaseFree Market Insights - Newser
Instil Bio (TIL) Q1 2026 Results Fall Short — EPS $-0.62, Revenue $N/AStock Idea Network - Newser
Trading Systems Reacting to (TIL) Volatility - Stock Traders Daily
Instil Bio (TIL) Q4 2025 Beat: Revenue $N/A, EPS Exceeds by SignificantMargin Improvement - Newser
Instil Bio Releases Q1 2026 Financial Results - AlphaStreet
Instil Bio, Inc. Reports First Quarter 2026 Financial Results – 8-K Filing Details and Key Highlights - Minichart
Instil Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Instil Bio, Inc. 1Q 2026: Net loss $4.2M, EPS $(0.62) — 10-Q Summary - TradingView
Instil Bio (NASDAQ: TIL) cuts Q1 loss as 2024 loan and going concern risk loom - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q1 2026 loss and extends cash runway beyond 2027 - Stock Titan
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
BRIEF-Instil Bio Q1 Basic EPS USD -0.62 - TradingView
Instil Bio evaluates new drug deals, $74.7M cash lasts past 2027 - Stock Titan
TradingKey - TradingKey
MSN Money - MSN
Why Instil Bio (TIL) deserves a deeper look right now (Smart Money Flows) 2026-05-08AI Powered Stock Picks - Newser
Instil Bio Inc expected to post a loss of 59 cents a shareEarnings Preview - TradingView
How Instil Bio Inc. (TIL) Affects Rotational Strategy Timing - Stock Traders Daily
TIL Technical Analysis | Trend, Signals & Chart Patterns | INSTIL BIO INC (NASDAQ:TIL) - ChartMill
The R&D spending story behind Instil Bio (TIL) innovation | Instil Bio posts 41% EPS beat, narrower loss, no revenueDebt/EBITDA - newser.com
Key Growth Drivers | Instil Bio posts 40.9% EPS beat topping analyst estimatesConsensus Forecast - newser.com
Instil Bio (TIL) Stock: Key Growth Drivers | Instil Bio posts 40.9% EPS beat topping analyst estimatesFast Rising Picks - Newser
(TIL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
[ARS] Instil Bio, Inc. SEC Filing - Stock Titan
Instil Bio (NASDAQ: TIL) sets 2026 vote and replaces Deloitte - Stock Titan
TIL Instil Bio delivers strong Q4 2025 EPS upside versus analyst estimates, shares edge slightly higher in today’s session.Market Expert Watchlist - Newser
TIL (Instil Bio Inc.) posts narrower Q4 2025 loss than consensus estimates, shares dip modestly in muted market reaction.Viral Trade Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Instil Bio, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
TIL Ownership | INSTIL BIO INC (NASDAQ:TIL) - ChartMill
Instil Bio (TIL) Stock Wall Street Rating (+0.11%) 2026-04-16Community Trade Ideas - Xã Thanh Hà
Responsive Playbooks and the TIL Inflection - Stock Traders Daily
Instil Bio (TIL) Price Target Increased by 24.53% to 67.32 - MSN
Breakout Move: Is Instil Bio Inc gaining market share2026 Setups & Community Verified Watchlist Alerts - baoquankhu1.vn
Will Instil Bio (TIL) Stock Outperform S&P 500 | Price at $7.99, Down 0.50%Buffered ETF - Newser
Instil Bio appoints RSM US as new auditor, replacing Deloitte & Touche - Investing.com India
Instil Bio appoints RSM US as new auditor, replacing Deloitte & Touche By Investing.com - Investing.com South Africa
Instil Bio (TIL) replaces Deloitte with RSM as independent auditor - Stock Titan
Understanding the Setup: (TIL) and Scalable Risk - Stock Traders Daily
TIL Technical Analysis & Stock Price Forecast - Intellectia AI
TIL PE Ratio & Valuation, Is TIL Overvalued - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Aug Levels: Is Instil Bio Inc forming bullish engulfing patterns2026 Institutional & Capital Efficient Trading Techniques - baoquankhu1.vn
Instil Bio Faces Heightened Cybersecurity Threats as Data Breach Risks Jeopardize Clinical Trials and Long-Term Strategy - TipRanks
Instil Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Instil Bio (NASDAQ: TIL) ends all R&D and warns on going concern - Stock Titan
Instil Bio 2025 10-K: $(71.4)M net loss, $(10.70) loss per share - TradingView
Instil Bio Q4 net loss per share narrows - TradingView
BRIEF-Instil Bio Q4 Basic EPS USD -1.21 - TradingView
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Globe and Mail
Bull Run: What analysts say about Instil Bio Inc stockMarket Volume Summary & Accurate Buy Signal Alerts - baoquankhu1.vn
Finanzdaten der Instil Bio Inc-Aktie (TIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Instil Bio Inc-Aktie (TIL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Laumas Sandeep | CFO and CBO |
Sep 10 '25 |
Sale |
23.39 |
30,000 |
701,667 |
0 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):